Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
2(66.7%)
Phase 2
1(33.3%)
3Total
Phase 1(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06295302Phase 2Recruiting

A Study to Explore the Efficacy and Safety of HWH486 in Adults With Chronic Spontaneous Urticaria

Role: lead

NCT03415659Phase 1Unknown

Phase I Clinical Study of HWH340 Tablet in Patients With Advanced Solid Tumors

Role: lead

NCT02374684Phase 1Completed

Tolerability, Safety and Pharmacokinetic Study Of Methosulide in Healthy Adult Subjects

Role: lead

All 3 trials loaded